New antisense oligonucleotide (ASO) treatments offer hope for patients with genetic forms of ALS, including SOD1-ALS, FUS-ALS and potentially C9orf72 expanded hexanucleotide repeat-ALS, which constitutes up to 40% of familial cases [9–13]. This evidence concerns the gene C9orf72 and amyotrophic lateral sclerosis.